Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Minerva Neurosciences (NERV) Shares Outstanding (Weighted Average) (2016 - 2026)

Minerva Neurosciences filings provide 3 years of Shares Outstanding (Weighted Average) readings, the most recent being $5.3 million for Q4 2021.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 86.92% to $5.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was $5.3 million, a 86.92% decrease, with the full-year FY2021 number at $5.3 million, down 86.92% from a year prior.
  • Shares Outstanding (Weighted Average) hit $5.3 million in Q4 2021 for Minerva Neurosciences, roughly flat from $5.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $42.7 million in Q1 2021 to a low of $5.3 million in Q2 2021.
  • Median Shares Outstanding (Weighted Average) over the past 3 years was $39.2 million (2020), compared with a mean of $28.6 million.
  • The widest YoY moves for Shares Outstanding (Weighted Average): up 9.05% in 2021, down 86.92% in 2021.
  • Minerva Neurosciences' Shares Outstanding (Weighted Average) stood at $39.0 million in 2019, then rose by 4.64% to $40.8 million in 2020, then tumbled by 86.92% to $5.3 million in 2021.
  • The last three reported values for Shares Outstanding (Weighted Average) were $5.3 million (Q4 2021), $5.3 million (Q3 2021), and $5.3 million (Q2 2021) per Business Quant data.